Source: Virtual Congress 2020 – Air pollution and comorbidities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Suska (Dnipro, Ukraine), K. Gashynova (Dnipro, Ukraine), V. Dmytrychenko (Dnipro, Ukraine). LSC - 2020 - Could the overweight influence bronchiectasis (B) exacerbations frequency (EF)?. 128

Member's Comments

No comment yet.

Related content which might interest you: Prevalence rates of symptoms and diagnoses of chronic bronchitis (CB), emphysema (E) and asthma (A), with or without airflow obstruction (AO), in two Italian general population samples Source: Eur Respir J 2005; 26: Suppl. 49, 595s Year: 2005 Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 LSC - 2020 - The lung DNA methylation profile of patients with COPD: relationship with smoking and airflow limitation severity. Source: Virtual Congress 2020 – Physiological and cellular mechanisms affecting pulmonary pathologies Year: 2020 Late Breaking Abstract - The population attributable risks (PAR) for chronic airflow obstruction (CAO) in 40 BOLD study centres worldwide. Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections Year: 2018 CAT in COPD phenotypes (POPE study) Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 Influence of cigarette smoking (CS) on the pulmonary complaints (PC), function of the external breathing (FEB) and quality of life (QL) in the practically healthy persons Source: Eur Respir J 2007; 30: Suppl. 51, 165s Year: 2007 COPD (C) and asthma (A) comorbidities in Italian primary care Source: Annual Congress 2010 - Comorbidity in obstructive airway disease Year: 2010 Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012 How does regular exercise affect dyspnoe (TDI) and quality of life (CAT) of COPD-patients 1 year after an inpatient pulmonary rehabilitation (PR)? Source: International Congress 2015 – Latest insights into pulmonary rehabilitation Year: 2015